Gutenberg Test Page

New Chief Medical Advisor

Internationally Renowned Cancer Immunologist Elizabeth M. Jaffee, M.D. Joins the Lustgarten Foundation

The Lustgarten Foundation announced today the appointment of Elizabeth M. Jaffee, M.D., the immediate past president of the American Association for Cancer Research (AACR), as its new Chief Medical Advisor. Dr. Jaffee is an internationally recognized expert in cancer immunology, with specific expertise in preclinical and early clinical development of immunotherapies for pancreatic cancer.

Learn More

Funding Artificial Intelligence Research

New Tools For Detecting and Treating Pancreatic Cancer

Collective logo

The Pancreatic Cancer Collective, the strategic partnership of Lustgarten Foundation and Stand Up To Cancer (SU2C) is funding two new million-dollar grants for computational approaches to identifying high-risk pancreatic cancer populations. The grant money will be used to develop new ways of identifying people who are at high risk for developing pancreatic cancer that will be based on their health records.

Artificial intelligence (AI) is a term that refers to machines that are programmed to mimic human reasoning. The goal of AI is to learn from failure and be able to provide the best recommendation for a specific subject. Whether it be solving equations, finding the best treatment options for cancer patients, or aiding in vehicle autonomy, AI is becoming a powerful resource across multiple industries.

“From diagnosing pancreatic cancer to determining which treatment approach may be best for each patient, we believe the field of AI holds great promise for patients and their families,” stated David A. Tuveson, MD, PhD, Lustgarten’s chief scientist, director of the Cancer Center at Cold Spring Harbor Laboratory and co-scientific leader of the Collective.

The two teams will each pursue a different approach to identifying individuals in the general population who are at high risk for pancreatic cancer. One will use molecular and genetic data taken from a variety of datasets to identify new and accessible ways to identify high-risk individuals. The other focuses on identification of high-risk individuals by applying machine learning analysis to real world data comprising radiological images, electronic medical records, and information collected by physicians. Each team will receive up to $1 million over two years.

 

Related Topics:

Learn more about the Pancreatic Cancer Collective
Find a screening program 

 

 

Learn More

New Therapies Challenge Grant

 

Lustgarten Foundation and Stand Up To Cancer, strategic partners in the Pancreatic Cancer Collective, offer comments on research published today in the journal Nature Medicine which describes a new therapeutic approach with promise for patients with pancreatic cancer. These researchers discovered a combination drug therapy that may effectively combat the disease. Based on this research, Martin McMahon, PhD, a cancer researcher at Huntsman Cancer Institute and professor of Dermatology at the University of Utah has received a Pancreatic Cancer Collective New Therapies Challenge Grant.

Learn More

Northwell Health Announces Sponsorship

Northwell Health a Presenting Sponsor of Five Walks

We are pleased to announce that Northwell Health Cancer Institute will be a presenting sponsor for our five Lustgarten Pancreatic Cancer Research Walks in the New York metropolitan area. With the support of Northwell Health, we will raise even more awareness and funding for pancreatic cancer research at our upcoming walks in New York City, Westchester, Brooklyn, Staten Island, and Long Island.

Our walks offer patients, survivors, and loved ones a day of hope where everyone is united in the shared goal of bringing awareness to this challenging disease. Together with Northwell Health, we are determined to raise critical funds for pancreatic cancer research and improve the survival outcomes for patients.

Northwell Sponsorship LI Walk

The Northwell Health Cancer Institute is in the early stages of developing a comprehensive pancreatic cancer center. The program’s major components will include surgical, radiation and medical oncology, interventional gastroenterology, pathology, radiology, endocrinology, palliative oncology, cancer genetics, nutritional counseling, social work and other services.

If you live in the New York metropolitan area, we encourage you to attend one of our five Northwell Health-sponsored walks, visit the Northwell Health tent on site, and learn more about our joint commitment to  changing patients’ lives and working toward a cure for pancreatic cancer.

Read the press release.

Learn more about pancreatic cancer, including information on diagnosis, treatment options, and clinical trials.

Walk For Research

Where 100% of Every Dollar Raised Goes Directly to Pancreatic Cancer Research.

New York City  |  March 31st
Pier 62-63 at Hudson River Park

Register Now!

Westchester  |  April 28th
Rye Playland Park

Register Now!

Brooklyn  |  July 21st
Marine Park Carmine Carro Center

Register Now!

Staten Island  |  September 8th
Franklin D. Roosevelt Boardwalk Beach

Register Now!

Long Island  |  October 6th
Jones Beach State Park

Register Now!

Learn More

Pancakes for a Purpose

The event’s founders did a fantastic job during their segment on WBTV News to talk about their 9th annual Pancakes for a Purpose event on Saturday, February 23rd at Blackfinn Ameripub – Ballantyne in Charlotte, North Carolina.

The event is in memory of Dave Anstadt and John Bradley, who both lost their fight with pancreatic cancer. All proceeds will benefit the Foundation.

This year, raffle items include a wine tasting at Total Wine, golf at Ballantyne Country Club, and gift cards to Sugar Creek and Oriental Trading, among many other prizes. Purchase tickets now!

Learn More

Stand Up To Cancer Summit

Leading Cancer Researchers Coming Together to Collaborate

Stand Up To Cancer (SU2C) hosted its 9th annual Scientific Summit in Santa Monica, CA where all of its funded researchers gather to provide updates, new grants are awarded and proposals are reviewed.  It’s a dynamic and inspiriting three days where more than 300 top scientists come together to discuss breakthroughs and updates in cancer research.

The Lustgarten Foundation is proud to be a part of this important meeting. Since 2012, we have built a robust and illustrious collaboration with SU2C, jointly funding 209 investigators across 31 leading research centers in both the United States and the United Kingdom, which is now the Pancreatic Cancer Collective.

The Collective scientists — comprised of 14 teams (three dream teams,  nine research teams and two convergence teams) are investigating pancreatic cancer in the field of immunotherapy, early detection, interception and new therapies. Two invited speakers, Dr. Brian Wolpin, head of our dedicated research lab at Dana Farber, and Dr. David Ryan, medical oncologist at Mass General Hospital and leader of one of the research teams, shared their novel data about a model risk for pancreatic cancer and the first pancreatic cancer clinical trial enrolling patients to be treated at home.

Additionally, during the summit, the Collective grants review committee evaluated proposals for Computational Approaches to Identifying High-Risk Pancreatic Cancer Populations with the goal of awarding two new grants.  The funding will help to develop tools to identify individuals in the general population who are at high risk for pancreatic cancer far earlier than they would otherwise be diagnosed, using information from existing health records.

 One Team was selected to identify high risk cohorts  through molecular and genetic data identifying new and accessible ways to identify high risk individuals and the other team will identify  high risk cohorts through real world data. The winners of these important new grants will be announced in the spring of 2019. 

 In case you missed it, check out the Facebook live from the Summit that was hosted by our chief scientist Dr. David Tuveson,

Learn More

Fourth Lab Opens

 

Lustgarten Foundation Opens Laboratory at Johns Hopkins Focused on Early Detection and Genetics of Pancreatic Cancer.

The Lustgarten Foundation announced today the opening of its fourth dedicated pancreatic cancer research laboratory at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland. The laboratory at Johns Hopkins University will join three other Lustgarten Foundation dedicated pancreatic cancer research laboratories, which include Cold Spring Harbor Laboratory, Dana-Farber Cancer Institute, and Massachusetts Institute of Technology.

Led by Dr. Bert Vogelstein, one of the most cited scientists and Director of the Ludwig Center Clayton Professor of Oncology and Pathology and a Howard Hughes Medical Institute investigator at The Johns Hopkins Medical School and Sidney Kimmel Comprehensive Cancer Center, the Lustgarten Laboratory at Johns Hopkins will leverage its expertise in early detection to intercept pancreatic cancer at an earlier stage when patients may be surgical candidates and will develop novel therapeutic approaches to treat pancreatic cancer based on genetic alterations.

 

 

 

 

Learn More

Pancreatic Cancer News


The fluid that feeds tumor cells

16. 4. 19 ladmin

Before being tested in animals or humans, most cancer drugs are evaluated in tumor cells grown in a lab dish. However, in recent years, there has been a growing realization that the environment in which these cells are grown does not accurately mimic the natural environment of a tumor, and that this discrepancy could produce […]

Genome-Wide Analysis Reveals New Strategies to Target Pancreatic Cancer

4. 4. 19 ladmin

For some cancers, initial treatment with chemotherapy brings positive, but only temporary, results: tumors shrink, but then rebound as the cancer becomes drug-resistant. This pattern of remission-resistance-relapse is particularly true for pancreatic cancer, an aggressive disease in which early success is often countered by eventual disease progression. To wit: The one-year relative survival rate for […]

Mayo Clinic finds 3 factors may extend life for pancreatic cancer patients

2. 4. 19 ladmin

 A new study from the Mayo Clinic found that a pre-surgery treatment plan may help extend life for advanced pancreatic cancer patients. According to Mayo researchers, most pancreatic cancer patients whose tumors grow outside the pancreas and encompass veins and arteries have been told the cancer is inoperable and they should prepare for an average survival time of 12 to 18 months. […]

Pancreatic Cancer Survival Odds Linked to Weight Before Age 50

1. 4. 19 ladmin

Need another reason to stay slim? People who are overweight have a greater risk of dying from pancreatic cancer, especially those who are carrying extra pounds before age 50, a new study suggests. “No matter what the age, there was some increase in pancreatic cancer deaths associated with excess weight. But the association was stronger […]

Trial to assess high-dose, MRI-guided radiation therapy for pancreatic cancer

30. 3. 19 ladmin

Researchers are launching a multi-institutional trial to test the effectiveness of precise, higher dose, MRI-guided radiation therapy to treat pancreatic cancer. “High-definition MRI and daily treatment plan adaptation allow us to deliver ablative radiation doses safely to [patients with pancreatic cancer] for the first time,” Parag Parikh, MD, director of gastrointestinal radiation oncology and MRI-guided […]

The Pancreatic Cancer Collective Funds Two New Research Teams Using Artificial Intelligence To Identify High-Risk Pancreatic Cancer Populations

30. 3. 19 ladmin

Computational Tools Seek to Identify Pancreatic Cancer Earlier, Provide More Opportunities for Timely, Effective Treatments The Pancreatic Cancer Collective, the strategic partnership of Lustgarten Foundation and Stand Up To Cancer (SU2C), today announced two, million-dollar grants for computational approaches to identifying high-risk pancreatic cancer populations. The grant money will be used to develop novel tools […]

Tumor-associated immune cells hinder frontline chemotherapy drug in pancreatic cancer

26. 3. 19 ladmin

A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug’s action, research led by the University of Michigan Rogel Cancer Center found. The chemotherapy drug gemcitabine is an anti-metabolite. It’s similar to normal metabolites taken up by the cell, but […]

Early Detection Is Possible for Pancreatic Cancer

15. 3. 19 ladmin

We can help people at risk, but it is much more challenging if most people think that early detection and prevention are impossible. Pancreatic cancer has a bad reputation. It is a terrible disease, but most people do not realize there are ways that early detection can help. When the “Jeopardy!” host, Alex Trebek, announced […]

Get Involved Today

Get inspired and connect with patients, survivors and loved ones who are all on the same journey.

Back to Top